Please login to the form below

Patient support blog series: Step 2 to a successful patient support programme

Break down those silos and work across internal and external stakeholders!


In my first blog post in this series ‘Step one:  Define your objectives and be able to measure and report on them’, we considered how to get clarity on the reasons why the organisation is investing in a PSP and on how you will measure success. Today we consider Step two.

Step two: Engage with stakeholders inside and outside of your organisation

Diseases don’t occur in a vacuum for those experiencing them, for those caring for patients, or for those trying to cure them. For any patient support programme to be successful, it needs to transcend the operational silos so prominent within the pharmaceutical industry – starting with internal stakeholders.

Internal stakeholders

Departments must work together, not just in sharing data, but in coordinating goals and objectives from the start.  Begin by mapping out all the internal stakeholders who will have a role in designing, delivering and using the outputs of the patient support programme.A multi-disciplinary workshop will allow you to understand what success looks like to each stakeholder. Certainly each department will expect different outcomes from the programme and will be able to use the data in different ways:

  • Market Access and HEOR teams will value real world data (e.g. disease outcomes, burden of disease and QoL) that can be used in peer-reviewed journals to support the value proposition and in negotiations with reimbursement authorities/formulary committees
  • Brand teams want successful launches, penetration and increased market share
  • Medical teams would like to see adherence and persistence data showing patients are staying on their medications as prescribed and clinical data showing the desired outcomes
  • Pharmacovigilance needs to monitor the performance of products in a wider population and look for uncommon side effects
Internal teams will be bought into the programme when they can see the benefits for patients and “what’s in it for them”. You will then need to work with these different departments as you design the programme, building in the steps to reach the desired outcomes.

Click here to read the full article, which goes on to consider how to engage with external stakeholders and understand their needs. 

Alternatively, contact Nagore.Fernandez@ashfieldhealthcare.com to find out how we can help you.  

17th August 2017

Share

Tags

Company Details

Ashfield

Contact Website

Address:
Ashfield House
Resolution Road
Ashby de la Zouch
Leicestershire
LE65 1HW
UK

Latest content on this profile

Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
Ashfield Meetings & Events, the largest full service event management agency specialising in serving the healthcare sector, has this month welcomed its largest intake of students to its highly successful university placement scheme.
Ashfield
‘Delivering healthcare events with certainty and impact’
Ashfield Meetings & Events launches new website Ashfieldmeetings.com
Ashfield
The Ashfield Solution - Accelerate product uptake and maximize ROI
A pioneering multichannel optimization model powered by advanced analytics with the ability to flex resources based on real time results.
Ashfield
Patient Engagement and Experience Conference, 16-17 May
Ashfield and S3 Connected Health, Silver Sponsors at the 3rd Annual Patient Engagement and Experience Conference in Amsterdam on 16-17 May, will be speaking on how digitally enhanced Patient Support Programmes can extend the continuity and relevance of care into patients’ everyday lives.
Ashfield
Ashfield will be exhibiting at ISMPP US
On 30 April - 2 May 2018, Ashfield Healthcare Communications will be exhibiting at the 14th Annual Meeting of ISMPP at the Gaylord National Resort & Convention Center, National Harbor, MD.
Ashfield
Putting the patient first
You’ve invested millions in the development of your new drug or therapy and have successfully completed clinical trials - now you are ready to launch. Data has been collected, efficacy is understood and side effects are recorded. But an important question remains: is your target patient population prepared?
Ashfield